TY - JOUR
T1 - Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes
AU - Jeyaratnaganthan, Nilani
AU - Højlund, Kurt
AU - Kroustrup, Jens Peter
AU - Larsen, Jens Fromholt
AU - Bjerre, Mette
AU - Levin, Klavs
AU - Beck-Nielsen, Henning
AU - Frago, Susana
AU - Hassan, A Bassim
AU - Flyvbjerg, Allan
AU - Frystyk, Jan
AU - Larsen, Jens Fromholt
N1 - Copyright © 2010 Elsevier Ltd. All rights reserved.
PY - 2010
Y1 - 2010
N2 - OBJECTIVE: The extracellular domain of the insulin-like growth factor II/mannose-6-phosphate receptor (IGF-II/M6P-R) is present in the circulation, but its relationship with plasma IGF-II is largely unknown. As IGF-II appears to be nutritionally regulated, we studied the impact of obesity, type 2 diabetes (T2D) and weight loss on circulating levels of IGF-II and its soluble receptor. METHODS: Twenty-three morbidly obese non-diabetic subjects were studied before and after gastric banding (GB), reducing their BMI from 59.3+/-1.8 to 52.7+/-1.6kg/m(2). Lean controls (n=10, BMI 24.2+/-0.5kg/m(2)), moderately obese controls (n=21, BMI 31.8+/-1.0kg/m(2)) and obese T2D patients (n=20, BMI 32.3+/-0.8kg/m(2)) were studied before and after a hyperinsulinaemic euglycaemic clamp. RESULTS: Morbidly obese subjects had elevated IGF-II/M6P-R and IGF-II levels, which both decreased following GB (IGF-II/M6P-R: from 0.97+/-0.038 to 0.87+/-0.030nmol/l, P=0.001; IGF-II: from 134+/-7 to 125+/-6nmol/l, P=0.01), as did fasting plasma glucose and insulin (P<0.05). However, the metabolic parameters correlated with neither IGF-II nor IGF-II/M6P-R. Obese diabetics had increased IGF-II/M6P-R as compared with lean and obese controls (0.82+/-0.031 vs. 0.70+/-0.033 vs. 0.74+/-0.026nmol/l; P<0.03) and levels were unaffected by clamp. In the latter cohort, IGF-II/M6P-R but not IGF-II correlated with HbA1c, and fasting plasma C-peptide, insulin and glucose (0.34
AB - OBJECTIVE: The extracellular domain of the insulin-like growth factor II/mannose-6-phosphate receptor (IGF-II/M6P-R) is present in the circulation, but its relationship with plasma IGF-II is largely unknown. As IGF-II appears to be nutritionally regulated, we studied the impact of obesity, type 2 diabetes (T2D) and weight loss on circulating levels of IGF-II and its soluble receptor. METHODS: Twenty-three morbidly obese non-diabetic subjects were studied before and after gastric banding (GB), reducing their BMI from 59.3+/-1.8 to 52.7+/-1.6kg/m(2). Lean controls (n=10, BMI 24.2+/-0.5kg/m(2)), moderately obese controls (n=21, BMI 31.8+/-1.0kg/m(2)) and obese T2D patients (n=20, BMI 32.3+/-0.8kg/m(2)) were studied before and after a hyperinsulinaemic euglycaemic clamp. RESULTS: Morbidly obese subjects had elevated IGF-II/M6P-R and IGF-II levels, which both decreased following GB (IGF-II/M6P-R: from 0.97+/-0.038 to 0.87+/-0.030nmol/l, P=0.001; IGF-II: from 134+/-7 to 125+/-6nmol/l, P=0.01), as did fasting plasma glucose and insulin (P<0.05). However, the metabolic parameters correlated with neither IGF-II nor IGF-II/M6P-R. Obese diabetics had increased IGF-II/M6P-R as compared with lean and obese controls (0.82+/-0.031 vs. 0.70+/-0.033 vs. 0.74+/-0.026nmol/l; P<0.03) and levels were unaffected by clamp. In the latter cohort, IGF-II/M6P-R but not IGF-II correlated with HbA1c, and fasting plasma C-peptide, insulin and glucose (0.34
U2 - 10.1016/j.ghir.2009.12.005
DO - 10.1016/j.ghir.2009.12.005
M3 - Journal article
SN - 1096-6374
VL - 20
SP - 185
EP - 191
JO - Growth Hormone & I G F Research
JF - Growth Hormone & I G F Research
ER -